The EGF-CSN6-FASN axis promotes tumor growth, suggesting a therapeutic strategy combining Orlistat (targeting pancreatic lipase in the gastrointestinal tract, inhibiting the production of fatty acids) and Cetuximab(targeting the epidermal growth factor receptor EGFR, blocking its activation and downstream signaling pathways) (27). The gene discussed is FASN; the disease is neoplasm.